U.S. PRODUCERS' QUESTIONNAIRE

GLYCINE FROM CHINA

This questionnaire must be received by the Commission by no later than April 27, 2011

See page 4 of the Instruction Booklet for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty order concerning glycine from China (Inv. No. 731-TA-718 (Third Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

| Address | | | | | | | | | |
|--|--|--|--|--|--|---|---|--|--|
| | | | State | | | | | | |
| World Wide | Web addre | ss | | | | | | | |
| Has your firm J | produced gly | cine (as defined | l in the instruction | n booklet) |) at any tir | ne since Janu | ary 1, 2005 | 5? | |
| □ NO | (Sign the cert | fication below as | nd promptly return o | only this p | page of the | questionnaire | to the Comm | nission) | |
| YES | | | arefully, complete a | | | | eturn the enti | ire | |
| | | | CERTIFICAT | TION | | | | | _ |
| | | | onse to this questi itted is subject to d | ionnaire | | | | | ıowledge |
| f and understand s of this certific ion provided in d by the Commis | that the inf cation I also this questic sion on the s | ormation subm grant consent onnaire and th ame or similar | onse to this questi itted is subject to d for the Commiss proughout this re merchandise. | tionnaire audit an esion, an review in | d verificated its emp | tion by the C loyees and c ner import-in | ommission contract pe njury proc | n. ersonnel, to eeedings or | use the |
| f and understand s of this certific ion provided in d by the Commis vledge that info ion, its employed ing the records | that the inf ration I also this questic sion on the s rmation sub es, and cont of this revie ne programs | grant consent prant consent onnaire and the ame or similar mitted in this fact personnel or related prand operations | onse to this questi itted is subject to of the Commiss aroughout this remerchandise. questionnaire rewho are acting in oceedings for whis of the Commissi | tionnaire audit an esion, an review in response in the ca nich this | d verificand d its emp any oth and thro pacity of informati | tion by the C loyees and c ner import-in ughout this Commission ion is submi | commission contract pe njury proce review m employees tted, or in | n. ersonnel, to eedings or nay be used s, for devel internal at | use the reviews d by the oping or |
| f and understand s of this certific ion provided in d by the Commis vledge that info ion, its employed ing the records o | that the inf ration I also this question sion on the s rmation sul- es, and cont of this revience programs gn non-disclo | grant consent grant consent onnaire and the ame or similar mitted in this fact personnel wor related prand operations on agreement. | onse to this questi itted is subject to of the Commiss aroughout this remerchandise. questionnaire rewho are acting in oceedings for whis of the Commissi | tionnaire audit an esion, an review in response in the ca nich this | d verificand d its emp any oth and thro pacity of informati | tion by the C loyees and c ner import-in ughout this Commission ion is submi | commission contract pe njury proce review m employees tted, or in | n. ersonnel, to eedings or nay be used s, for devel internal at | use the reviews d by the oping or |
| f and understand s of this certific ion provided in d by the Commis vledge that info ion, its employed ing the records o ngs relating to th personnel will sig | that the inf ration I also this question sion on the s rmation sul- es, and cont of this revience programs gn non-disclo | grant consent ornaire and the ame or similar mitted in this fact personnel wor related pressure agreement. Title of Author and operations | onse to this questi itted is subject to of the Commiss aroughout this remerchandise. questionnaire rewho are acting in occedings for whis of the Commissints. | tionnaire audit an esion, an review in esponse in the ca nich this rion purs | d verifical d its emp any oth and thro pacity of informati uant to 5 | tion by the C loyees and c ner import-in sughout this Commission ion is submit U.S.C. Appo | commission contract pe njury proce review m employees tted, or in | n. ersonnel, to eedings or nay be used s, for devel internal at | use the reviews d by the oping or |

PART I.—GENERAL INFORMATION

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

| OMB statisticsPlease report below the firm of preparing the reply to this question. | | | | cost to your |
|---|--------------------|------------------|----------------|--------------|
| | | hours | S | dolla |
| OMB feedbackWe are interested in questionnaire in general or the clarity or response or send them to the above add | of specific questi | • | | |
| Establishments coveredProvide the questionnaire (see page 3 of the instruction publicly traded, please specify the stock provided the stock pro | ction booklet for | reporting guidel | | • |
| | | arading symbol. | | |
| Position regarding continuation of of antidumping duty order currently in plantidumping duty order currently in plantidumping duty order currently in plantidumping duty order currently in plantidum duty order currently duty duty order currently duty duty duty duty duty duty duty dut | rderDo you su | ipport or oppose | e continuation | n of the |

PART I.--GENERAL INFORMATION--Continued

| ☐ No | YesList | the following information. | |
|----------------|--|-----------------------------|--|
| Firm name | | Address | Extent of ownersh |
| | | | |
| | | | |
| domestic or fo | oreign, that are | | m have any related firms, either e from China into the United Stat nited States? |
| ☐ No | YesList | the following information. | |
| Firm name | | Address | <u>Affiliation</u> |
| domestic or fo | oreign, that are or ded States or that | engaged in importing glycin | ur firm have any related firms, eith e from countries other than Chincine from countries other than Chin |
| ☐ No | YesList | the following information. | |
| | 1 , | Address | <u>Affiliation</u> |
| Firm name an | <u>id country</u> | Addiess | <u>Attitution</u> |

PART I.--GENERAL INFORMATION--Continued

| engaged in the prod | detion of glyenie. | |
|---------------------------------------|--|---|
| □ No □ | YesList the following information. | |
| Firm name | Address | <u>Affiliation</u> |
| | | |
| | | |
| | | |
| business plan. Doe | Parts II and IV of this questionnaire we s your company or any related firm have cribe, discuss, or analyze expected mar | ve a business plan or any internal |
| business plan. Doe documents that des | s your company or any related firm have | ve a business plan or any internal ket conditions for glycine? cuments. If you are not providing t |
| business plan. Doe documents that des | s your company or any related firm have eribe, discuss, or analyze expected mar YesPlease provide the requested doc | ve a business plan or any internal ket conditions for glycine? cuments. If you are not providing t |
| business plan. Doe documents that des | s your company or any related firm have eribe, discuss, or analyze expected mar YesPlease provide the requested doc | ve a business plan or any internal ket conditions for glycine? cuments. If you are not providing t |
| business plan. Doe documents that des | s your company or any related firm have eribe, discuss, or analyze expected mar YesPlease provide the requested doc | ve a business plan or any internal ket conditions for glycine? cuments. If you are not providing t |

PART II.—TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from **Stefania Pozzi Porter** (202-205-3177, **Stefania.PozziPorter@usitc.gov**). Supply all data requested on a <u>calendar-year</u> basis.

| II-1. | Please identify the individual to be c part II. | ontacted regarding the confidential information requested in |
|-------|--|---|
| | Name and title: | |
| | Please indicate the manner by which part II with questions regarding the s | Commission staff may contact the individual responsible for submitted confidential information. |
| | E-mail: | Telephone: () |
| | Fax: () | |
| II-2. | <u>Changes in operations</u> ,Please ind changes in relation to the production | icate whether your firm has experienced any of the following of glycine since January 1, 2005. |
| | (check as many as appropriate) | (please describe) |
| | plant openings | |
| | plant closings | |
| | relocations | |
| | expansions | |
| | acquisitions | |
| | onsolidations | |
| | prolonged shutdowns or production curtailments | |
| | revised labor agreements | |
| | other (e.g., technology) | |

| your operat future? | ions or organization (as noted above) relating to the production of glycine in the |
|----------------------------|--|
| □ No | YesSupply details as to the time, nature, and significance of such change and provide underlying assumptions, along with relevant portions o business plans or other supporting documentation that address this issue. Include in your response a specific projection of your firm capacity to produce glycine (in 1,000 pounds) for 2011 and 2012 |
| | |
| anticipate a relating to t | d changes in operations in the event the order is revokedWould your firm my changes in the character of your operations or organization (as noted above) the production of glycine in the future if the antidumping duty order on glycine from |
| anticipate a relating to t | ny changes in the character of your operations or organization (as noted above) |

| pro | t the following ir oduction capacity periods indicate | and produ | | | | |
|---|---|--------------|--------|------|------------------------------|---|
| Product | <u>Period</u> | | | | apacity and ate if differ | _ |
| | (Quantiti | / in 1,000 p | onuqe) | | | _ |
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | |
| Overall Production Capacity | | | | | | |
| Production of: Glycine | | | | | | |
| Other product 1 | | | | | | |
| Other product 2 | | | | | | Ī |
| Constraints on production. | | | | | | |
| Production capacity. Production shiftingIs you in response to a relative change the same equipment and/or la | ge in the price of | | | | | |

PART II.—TRADE AND RELATED INFORMATION--Continued

II-8. <u>Trade data.</u>—Report your firm's production capacity, production, shipments, inventories, and employment related to the production of glycine in your U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

| Quantity | (in 1,000 p | ounds) and | d value (in | \$1,000) | | |
|--|-------------|-------------|--------------|--------------|-------------|------------------|
| | | | Calend | lar year | | |
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 |
| Average production capacity ¹ (quantity) (A) | | | | | | |
| Beginning-of-period inventories (quantity) (B) | | | | | | |
| Production (quantity) (C) | | | | | | |
| U.S. shipments: Commercial shipments: quantity (D) | | | | | | |
| value (E) | | | | | | |
| Internal consumption: ² quantity (F) | | | | | | |
| value (G) | | | | | | |
| Transfers to related firms: ² quantity (H) | | | | | | |
| value (I) | | | | | | |
| Export shipments: ³ quantity (J) | | | | | | |
| value (K) | | | | | | |
| End-of-period inventories (quantity) (L) | | | | | | |
| Channels of distribution: U.S. shipments to distributors (quantity) (M) | | | | | | |
| U.S. shipments to end users (quantity) (N) | | | | | | |
| Employment data: Average number of PRWs (number) (O) | | | | | | |
| Hours worked by PRWs (1,000 hours) (P) | | | | | | |
| Wages paid to PRWs (value) (Q) | | | | | | |
| The production capacity (see of the production capacity, and explain an necessary). | per year. F | Please desc | ribe the me | thodology u | sed to calc | erating ulate |
| ² Internal consumption and transevent that you use a different basis cost plus, <i>etc.</i>) and provide value date. | for valuing | these trans | actions, ple | ease specify | that basis | |
| ³ Identify your principal export m | narkets: | | | | | |

Reconciliation of trade data.--

II-9.

| | each period (i.e., | in each colur | reported in question II-8 should reconcile as follows in nn): | | | | |
|---|---|--|---|--|--|--|--|
| | Reconciliation B + C - D - F - | H – J = L | Do these data reconcile? ☐ Yes ☐ NoPlease explain | | | | |
| | D + F + H = M + | · N | Do these data reconcile? Yes NoPlease explain | | | | |
| (b) | beginning-of-per | Please note that the quantities reported for end-of-period inventories should equal the beginning-of-period inventories reported in the subsequent calendar year (<i>i.e.</i> , line L of year 2005 should equal line B of year 2006). Do these data reconcile for each adjacent calendar year? | | | | | |
| | Yes. | □ NoP | lease explain. | | | | |
| | | | | | | | |
| | | | earketing rights to all transfers, and whether the related ses other than your firm. | | | | |
| | | | | | | | |
| Pleas | | oduction proc | ess your firm uses to produce glycine. (Check all that | | | | |
| apply Buth Buth | .) ydrogen cyanide (drous ammonia, soc | "HCN") prod | ess your firm uses to produce glycine. (Check all that ess (This process uses formaldehyde, hydrogen cyanide e, and sulfuric acid as raw material inputs and/or catalysts is a distinct intermediate product in this process.) | | | | |
| apply I H anhyo to pro M anhyo input | ydrogen cyanide (drous ammonia, socoduce glycine. Sodo | "HCN") prodium hydroxid um glycinate id ("MCA") i | <u>cess</u> (This process uses formaldehyde, hydrogen cyanide, and sulfuric acid as raw material inputs and/or catalysts | | | | |

| II-12. Purchases Other than dir 1, 2005? (See definitions i | | | | e purchased | l glycine sir | ice January |
|--|--|---------------|----------------------|--------------|---------------|-------------|
| , | Please indica source, pleas purchases be | se elaborate) | and report | the quantity | | |
| Reasons: | | | | | | |
| (Qu | antity in 1,00 | 00 pounds, va | alue <i>in \$1,0</i> | 00) | | |
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 |
| PURCHASES FROM U.S. IMPORTERS ¹ OF GLYCINE FROM.— China: quantity | - | | | | | |
| value | | | | | | |
| All other countries: quantity | | | | | | |
| value | | | | | | |
| PURCHASES FROM DOMESTIC PRODUCERS: ² quantity | | | | | | |
| value | | | | | | |
| PURCHASES FROM OTHER SOURCES: quantity | | | | | | |
| Value | | | | | | |
| Please list the name of the imporsource, please identify the source for expense of the list the name of the dome. Please list the name of the dome. | each listed sup | pplier. | | | | iffer by |
| | | | | | | |
| II-13. Toll productionSince Ja definition in the instruction No YesN | • / | garding the p | production | of glycine? | C | ment (see |
| II-14. <u>FTZ</u> Does your firm prod | | | | | | · |
| | dentify FTZ(| | | | | |

| Direct | imports | -Since Janu | ary 1, 2005, ha | is your min i | inported gry | cinc: | |
|---|--|--|--|--|--|---|---|
| ☐ No | | | MPLETE AN | | A U.S. IMP | ORTERS | , |
| | | <u>U</u> | <u>UESTIONNA</u> | <u>IRE</u> | | | |
| | | | e report the quaquality of the g | | | | ments by grade on sold). |
| | | | U.S. Sh | ipments | | | |
| | | Produ | ıct | Quantit | y (in 1,000 j | oounds) | |
| | Pharma | ceutical g | rade | | | | |
| | USP gr | ade | | | | | |
| | Technic | cal grade | | | | | |
| | Other g | rade | _ | | | | |
| produc flow, c | s of glycin etion, U.S. capital exp | e from Chir shipments, enditures, re | na in terms of i inventories, pu | rchases, emp velopment ex | our firm's policyment, revipenditures, | roduction venues, coand asset v | capacity, sts, profits, cash values. You may |
| produc flow, c | s of glycin etion, U.S. capital exp | e from Chir shipments, enditures, re | na in terms of i inventories, pu esearch and dev | ts effect on y rchases, emp velopment ex | our firm's policyment, revipenditures, | roduction venues, coand asset v | capacity, sts, profits, cash values. You may |
| produc flow, c | s of glycin etion, U.S. capital exp | e from Chir shipments, enditures, re | na in terms of i inventories, pu esearch and dev | ts effect on y rchases, emp velopment ex | our firm's policyment, revipenditures, | roduction venues, coand asset v | capacity, sts, profits, cash values. You may |
| product flow, c wish to wish to Likely capacity profits relatin | s of glycin etion, U.S. capital expo o compare reffect of rety, product , cash flow | e from Chinshipments, enditures, reyour firm's revocation ion, U.S. should be considered as a control of the co | na in terms of i inventories, pure search and developerations before the operations are the o | ts effect on y rchases, emp velopment ex ore and after uld your firm atories, purch earch and dev | our firm's poloyment, revenue penditures, at the imposition anticipate a ases, employelopment experience of the imposition of the impositi | any change | capacity, sts, profits, cash values. You may order. |
| product flow, c wish to wish to Likely capacity profits relatin | effect of response to the product of | revocation ion, U.S. shoduction of revoked? YesSuparabu | of orderWornipments, inverse glycine in the sport of t | ts effect on y rchases, empy elopment extore and after uld your firm atories, purchearch and defuture if the ato the time, nerlying assume other support | anticipate a ases, employelopment extintidumping ature, and sinptions, along | any change yment, rev penditure duty order | capacity, sts, profits, cash values. You may order. es in its producti renues, costs, es, or asset value |
| Likely capaci profits relatin China | effect of response to the product of | revocation ion, U.S. shoduction of revoked? YesSuparabu | of orderWonipments, inverpenditures, resigned provide under a puly details as and provide under a plans of the plans of | ts effect on y rchases, empy elopment extore and after uld your firm atories, purchearch and defuture if the ato the time, nerlying assume other support | anticipate a ases, employelopment extintidumping ature, and sinptions, along | any change yment, rev penditure duty order | capacity, sts, profits, cash values. You may order. es in its productivenues, costs, es, or asset value or on glycine from e of such change evant portions o |

PART III.—<u>FINANCIAL INFORMATION</u>

Address questions on this part of the questionnaire to Charles Yost (202-205-3432, Charles.Yost@usitc.gov).

| III-1. | Please identify the individual to be contacted regarding the confidential information requested in part III? |
|----------|---|
| | Name and title: |
| | Please indicate the manner by which Commission staff may contact the individual responsible for part III with questions regarding the submitted confidential information. |
| | E-mail: Telephone: () |
| | Fax: () |
| III-2. | General guidance:Financial data are requested on a product-line basis; the product is glycine, as defined in the instruction booklet. Inputs your firm receives from affiliates to produce glycine should be stated at cost (i.e., intra-firm profits eliminated, see question III-7) while transfers of glycine to related affiliates should be stated at fair market value. Please report all sales on an f.o.b. basis. Total sales in this section should equal total shipments plus exports in Part II, page 8 (trade data) of this questionnaire. PLEASE REPORT ALL FINANCIAL DATA ON A CALENDAR YEAR BASIS. |
| III-3. | Accounting systemBriefly describe your financial accounting system. |
| | a) When does your fiscal year end (month and day)? |
| | e) Accounting basis: |
| profit-d | The Commission may request that your company submit copies of its financial statements, including internal and-loss statements for the division or product group that includes glycine, as well as those statements and neets used to compile data for your firm's questionnaire response. |
| III-4. | Cost accounting system.—Briefly describe your cost accounting system (e.g., standard cost, job |
| | order cost, etc.). |
| | |
| | |
| | |

PART III.—<u>FINANCIAL INFORMATION</u>--Continued

| Other productsPlease list a produced glycine, and provide most recent fiscal year: | | | | |
|---|----------------------|--------------------------|--------|----------------------|
| <u>Products</u> | | | | Share of sales |
| _ | | | | |
| _ | | | | |
| _ | | | | |
| | | | | |
| Raw materials from related energy, or any other services) | used in the product | tion of glycine | from a | |
| YesContinue to question | | | | • |
| Inputs from related firmsI production of glycine that you consolidated with the financial | r firm receives from | m related partic | | |
| <u>Inputs from related firms.</u> I production of glycine that you | r firm receives from | m related partions firm. | | se financial stateme |

PART III.—<u>FINANCIAL INFORMATION</u>--Continued

| III-70 | . <u>Inputs from related firms at cost.</u> —All intercompany profit on inputs <u>purchased from related parties</u> should be eliminated from the costs reported to the Commission in question III-10 (i.e. costs reported in question III-10, to the extent that they reflect inputs purchased from related parties, should only reflect the related party's cost and not include an associated profit component). Reasonable methods for determining and eliminating the associated profit on inpurchased from related parties are acceptable. | | | | | | |
|--|---|---|--|---|--|---|---|
| Has your firm complied with the Commission's instructions regarding costs a inputs purchased from related parties? | | | | | | costs associa | ted with |
| | ☐ Yes ☐ No—Please contact Charles Yost (202-205-3432, Charles.Yost@usitc.gov) | | | | | | |
| III-8. | Nonrecurring char question III-10, plea particular expense/c a brief description o would include, but a due to restructuring | ost line items f the charges, are not limited | the schedule from questic and the asso to, items su | e below the son III-10 who ciated value ch as asset w | specific nonrere the assoc s (in \$1,000) | ecurring char iated charges Nonrecurri | ges, the are included ing charges |
| | | | T | | ears ended | _ | |
| L | Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 |
| | Non-recurring charges: and indicate the particula 1. | | | | | | |
| <u> </u> | 2. | | | | | | |
| | 3. | | | | | | |
| — | 4. | | | | | | |
| | | | | | | | |
| | 5 | | | | | | |
| — | 5. | | | | | | |
| | 5. 6. 7. | | | | | | |

PART III.—FINANCIAL INFORMATION--Continued

III-10. Operations on glycine.—Report the revenue and related cost information requested below on the glycine operations of your U.S. establishment(s). Do not report resales of purchased glycine.

Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost. Provide data on a calendar year basis for the six most recently completed years in chronological order from left to right. If your firm was involved in tolling operations (either as the toller or as the tollee) please contact Charles Yost (202-205-3432, Charles.Yost@usitc.gov) before completing this section of the questionnaire.

| Quantity (in 1,000 pounds) and value (in \$1,000) | | | | | | |
|---|------|------|------|------|------|------|
| ltem | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 |
| Net sales quantities: ³ Commercial sales | | | | | | |
| Internal consumption | | | | | | |
| Transfers to related firms | | | | | | |
| Total net sales quantities | | | | | | |
| Net sales values: ³ Commercial sales | | | | | | |
| Internal consumption | | | | | | |
| Transfers to related firms | | | | | | |
| Total net sales values | | | | | | |
| Cost of goods sold (COGS): ⁴ Raw materials, net of by-products | | | | | | |
| Direct labor | | | | | | |
| Other factory costs | | | | | | |
| Total COGS | | | | | | |
| Gross profit or (loss) | | | | | | |
| Selling, general, and administrative (SG&A) expenses: Selling expenses | | | | | | |
| General and administrative expenses | | | | | | |
| Total SG&A expenses | | | | | | |
| Operating income (loss) | | | | | | |
| Other income and expenses: Interest expense | | | | | | |
| All other expense items | | | | | | |
| Continued Dumping and Subsidy Offset Act funds received ⁵ | | | | | | |
| All other income items | | | | | | |
| All other income or expenses, net | | | | | | |
| Net income or (loss) before income taxes | | | | | | |
| Depreciation/amortization included above | | | | | | |
| 1 | | | | | | |

¹ Include only sales (whether domestic or export) and costs related to your <u>U.S. manufacturing operations</u>.

² Please eliminate any profits or (losses) on inputs from related firms pursuant to question III-7.

³ Less discounts, returns, allowances, and prepaid freight. The total quantities and values should approximate the corresponding total shipment quantities and values reported in Part II of this questionnaire.

⁴ COGS should include costs associated with sales, internal consumption and transfers to related firms.

⁵ Please report funds received under this act in the period(s) in which they were received. Do not report these funds as an offset to operating expenses.

PART III.—<u>FINANCIAL INFORMATION</u>--Continued

III-11. <u>Asset values.</u>—Report the total assets associated with the production, warehousing, and sale of glycine. If your firm does not maintain some or all of the specific asset data in the normal course of business, please estimate it based upon some rational method (such as production, sales, or costs) that is consistent with your cost allocations in the previous question. Your finished goods inventory value should reconcile with the inventory quantity data reported in Part II. Provide data as of the end of your six most recently completed fiscal years in chronological order from left to right.

| | | | Value (ii | n \$1,000) | | |
|---|------|-------------|-----------|------------|------|-------------|
| Item | 2005 | <u>2006</u> | 2007 | 2008 | 2009 | <u>2010</u> |
| ASSETS associated with the production, warehousing, and sale of product: 1. Current assets: A. Cash and equivalents | | | | | | |
| B. Accounts receivable, net | | | | | | |
| C. Finished goods inventories | | | | | | |
| D. All other (describe:) | | | | | | |
| E. Total current assets (lines 1.A. through 1.D.) | | | | | | |
| Property, plant, and equipment A. Original cost of property, plant, and equipment | | | | | | |
| B. Less: Accumulated depreciation | | | | | | |
| C. Equals: Book value of property, plant, and equipment | | | | | | |
| 3. Other (describe:) | | | | | | |
| 4. Total assets (lines 1.E., 2.C., and 3) | | | | | | |

III-12. <u>Capital expenditures and research and development expenses.</u>—Report your firm's capital expenditures and research and development expenses on glycine. Provide data on a calendar year basis for the six most recently completed years in chronological order from left to right.

| | | | Value (ii | n \$1,000) | | |
|-----------------------------------|---------------|------|-----------|------------|------|-------------|
| | Calendar year | | | | | |
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | <u>2010</u> |
| Capital expenditures | | | | | | |
| Research and development expenses | | | | | | |

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Aimee Larsen (202-205-3179, Aimee.Larsen@usitc.gov).

| IV-1. | Please identify the individual to be contapart IV? | acted regarding the confidential information requested in |
|-------|---|--|
| | Name and title: | |
| | Please indicate the manner by which Co part IV with questions regarding the sub | mmission staff may contact the individual responsible for mitted confidential information. |
| | E-mail: | Telephone: () |
| | Fax: () | |

PRICE DATA

This section requests quarterly quantity and value data, f.o.b. your U.S. point of shipment, for your commercial shipments to unrelated U.S. customers since 2005 of the following products produced by your firm.

- <u>Product 1</u>.-- Pharmaceutical-grade glycine A white, odorless, crystalline powder with a sweet taste, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), and with no more than 70 ppm chloride, no more than 65 ppm sulfate, and no more than 10 ppm heavy metals.
- **Product 2.-- USP-grade** glycine A white, odorless, crystalline powder with a sweet taste, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), and with no more than 70 ppm chloride, no more than 65 ppm sulfate, no more than 20 ppm heavy metals, and not otherwise qualifying as pharmaceutical-grade glycine.
- **Product 3.--Technical-grade** glycine A white, off-white, or slightly yellow crystalline powder, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), with no more than 200 ppm sulfates, and not otherwise qualifying as USP-grade glycine.

Note.—The pricing product data should reflect the end use for which the glycine in question is sold. The purity requirements listed for each pricing product reflect minimum purity requirements for end users in those markets. Any glycine that could be sold into a higher purity end use but is not should be recorded as a sale to the market into which it is sold. For example, if a producer produces glycine meeting the specifications for use in deodorant applications (USP grade) but sells that product for metal complexing (technical grade), that sale should be recorded as a technical grade sale.

Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to you (i.e., should be net of all deductions for discounts or rebates). See instruction booklet.

IV-2. **Pricing data.--**Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

| | (Quantity <i>in p</i> o | | | uct 2 | Produ | ict 3 |
|---|-------------------------|----------------|-----------------|----------------|------------------|-----------|
| Period of shipment | Quantity | Value | Quantity | Value | Quantity | Value |
| 2005: | Quantity | Tuido | Quartity | 74.40 | Quantity | Value |
| January-March | | | | | | |
| April-June | | | | | | |
| July-September | | | | | | |
| October-December | | | | | | |
| 2006: | | | | | | |
| January-March | | | | | | |
| April-June | | | | | | |
| July-September | | | | | | |
| October-December | | | | | | |
| 2007: | | | | | | |
| January-March | | | | | | |
| April-June | | | | | | |
| July-September | | | | | | |
| October-December | | | | | | |
| 2008: | | | | | | |
| January-March | | | | | | |
| April-June | | | | | | |
| July-September | | | | | | |
| October-December | | | | | | |
| 2009: | | | | | | |
| January-March | | | | | | |
| April-June | | | | | | |
| July-September | | | | | | |
| October-December | | | | | | |
| 2010: January-March | | | | | | |
| April-June | | | | | 1 | |
| July-September | | | | | | |
| October-December | | | | | | |
| ¹ Net values (<i>i.e.</i> , gross sales value | ا الحو عاا طنوه | nunte allow | ances rehator | nrangid fro | ight and the v | value of |
| returned goods), f.o.b. your U.S. point of | | ourito, alluwa | ances, repates | s, prepaid lit | agui, and the v | alue UI |
| ² Pricing product definitions are pro | | rst page of I | Part IV. | | | |
| | | | | | | |
| NoteIf your product does not exactly | meet the produ | ıct specifica | tions but is co | mpetitive wi | th the specified | d product |
| provide a description of your product: | | | | | | |
| Draduat 1: | | | | | | |
| Product 1: | | | | | | |
| Product 1: Product 2: | | | | | | |

| (chec | e setting How does your fire the street of the setting How does your fire the street of the setting How does your fire the setting How does your fire the setting | m issues price lists, please | include a copy of a recent price lis |
|-----------------|--|--|--|
| T1 | ransaction by transaction | Contracts | Set price lists |
| O | therPlease describe: | | |
| Disco | | e and describe your firm's | discount policies (check all that |
| □Q | uantity discounts | Annual total volume di | scounts |
| o [| therPlease describe: | | |
| | | | |
| | | | |
| - | | | |
| <u>Prici</u> | ng terms for glycine | | |
| (a) | • | | -produced glycine (e.g., 2/10 net 3 |
| (b) | On what basis are your pr | | 11 12 (1 1) |
| | F.o.bPlease specify | rices of domestic glycine upoint: | |
| glycii 12 me | F.o.bPlease specify ract versus spotApproxime in 2010 were on a (1) long | point:nately what share of your g-term contract basis (multiple deliveries) | |
| glycii 12 me | F.o.bPlease specify ract versus spotApproximate in 2010 were on a (1) long onths), (2) short-term contract | point:nately what share of your g-term contract basis (multiple deliveries) | Delivered firm's sales of its U.Sproduced tiple deliveries for more than sup to and including 12 months), |
| glycii 12 me | F.o.bPlease specify ract versus spotApproximate in 2010 were on a (1) long onths), (2) short-term contract out sales basis (for a single detection). | point:nately what share of your g-term contract basis (multiple deliveried basis)? | Delivered firm's sales of its U.Sproduced tiple deliveries for more than sup to and including 12 months), |
| glycii 12 me | F.o.bPlease specify ract versus spotApproximate in 2010 were on a (1) long onths), (2) short-term contract sales basis (for a single description of sales). Type of sale | point:nately what share of your g-term contract basis (multiple deliveried basis)? | Delivered firm's sales of its U.Sproduced tiple deliveries for more than sup to and including 12 months), |

| IV-7. | Long-term contract provisionsIf you sell on a long-term contract basis, please answer the | | | | | | |
|--------|---|---|---|--|--|--|--|
| | followi | ing questions with respect | to provisions of a typical long- | term contract. | | | |
| | (a) | What is the average dura | tion of a contract? | | | | |
| | (b) | Can prices be renegotiate | ed during the contract period? | ☐ Yes ☐ No | | | |
| | (c) | Does the contract fix quantity, price, or both? Quantity Price Both | | | | | |
| | (d) | Does the contract have a | meet or release provision? | ☐ Yes ☐ No | | | |
| IV-8. | | | If you sell on a short-term co to provisions of a typical short- | | | | |
| | (a) | (a) What is the average duration of a contract? | | | | | |
| | (b) | Can prices be renegotiate | ed during the contract period? | ☐ Yes ☐ No | | | |
| | (c) | Does the contract fix quantity, price, or both? Quantity Price Both | | | | | |
| | (d) | Does the contract have a | meet or release provision? | ☐ Yes ☐ No | | | |
| IV-9. | | imesWhat is the average ur firm's sales of your U.S. | | 's order and the date of delivery | | | |
| | | Source | Share of sales in 2010 | <u>Lead time</u> | | | |
| | From | inventory | | | | | |
| | Produ | iced to order | | | | | |
| | Total | | 100 % | | | | |
| IV-10. | Shippi | ng information | | | | | |
| | (a) | (a) What is the approximate percentage of the total delivered cost of glycine that is accounted for by U.S. inland transportation costs? percent. | | | | | |
| | (b) | Who generally arranges t | he transportation to your custon haser | mers' locations? (check one) | | | |
| | (c) | | sales are delivered within 100 to 1,000 miles? perce | miles of your production facility ent. Over 1,000 miles? | | | |

PART IV.--PRICING AND MARKET FACTORS--Continued

IV-11. <u>Geographical shipments.</u>— What is the geographic market area in the United States served by your firm's glycine? (check all that apply)

| | Geographic area | if applicable |
|--------|--|----------------------|
| | NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT. | |
| | MidwestIL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI. | |
| | SoutheastAL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV. | |
| | Central SouthwestAR, LA, OK, and TX. | |
| | MountainsAZ, CO, ID, MT, NV, NM, UT, and WY. | |
| | Pacific CoastCA, OR, and WA. | |
| | Other .–All other markets in the United States not previously listed, including AK, HI, PR, VI, among others. | |
| IV-12. | Changes in end usesHave there been any changes in the end uses of glycin | e since 2005? |
| | ☐ No ☐ YesPlease describe. | |
| IV-13. | Anticipated changes in end usesDo you anticipate any changes in terms of glycine in the future? No YesPlease describe and identify the time period | f the end uses of |
| IV-14. | Pharmaceutical grade glycine.—Please describe and comment on the market grade glycine. How is it different from the market for USP grade glycine? W to entry into this market? What is the role of government regulation in setting standards? | hat are the barriers |
| | | |

| | ıbstitute oroduct | Description of applications and end uses in which this substitute can be used | Have changes in the prices of this substitute affected the price of glycine since January 1, 2005? Please explain. |
|--------|----------------------|---|---|
| 1. | | | □ No |
| 2. | | | □ No □ Yes □ |
| 3. | | | □ No |
| IV-16. | | | been any changes in the number or types of products that |
| IV-16. | | substitutesHave there be ituted for glycine since 200 YesPlease explain | 05? |

| IV-18. | Raw materials.— | | | | | |
|--------|-----------------|---|--|--|--|--|
| | (a) | To what extent have changes in the prices of raw materials affected your firm's selling prices for glycine since 2005? | | | | |
| | (b) | Do you anticipated changes in your raw material costs in the foreseeable future? No YesPlease explain. | | | | |
| IV-19. | supply | <u>tes in factors affecting supply.</u> —Have any changes occurred in any other factors affecting (e.g., changes in availability or prices of energy or labor; transportation conditions; etion capacity and/or methods of production; technology; export markets; or alternative | | | | |
| | produc | etion opportunities) that affected the availability of U.Sproduced glycine in the U.S. esince 2005? | | | | |
| | □ No | YesPlease note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices. | | | | |
| | | | | | | |
| IV-20. | Availa | bility of supply (U.Sproduced) | | | | |
| | (a) | Do you anticipate any changes in terms of the availability of U.Sproduced glycine in the U.S. market in the future? | | | | |
| | | ☐ Increase ☐ No change ☐ Decrease | | | | |
| | (b) | If you anticipate changes in supply, please explain. | | | | |
| | | | | | | |

| Availability of supply (nonsubject)Has the availability of NONSUBJECT glycine (i.e., glycine imported from countries other than China) changed since 2005? | | | |
|---|--|--|--|
| ☐ No ☐ YesPlease explain. | | | |
| | | | |
| | | | |
| Export constraints. Can your firm shift its sales of glycine between the U.S. market and alternative country markets? | | | |
| □ No □ Yes | | | |
| Please describe any contracts, other sales arrangements, or other constraints that would prevent or retard your firm from shifting glycine between the U.S. and alternative country markets within a 12-month period. | | | |
| | | | |
| | | | |
| <u>Product changes.</u> —Have there been any significant changes in the product range, product mix, or marketing of glycine since 2005? | | | |
| ☐ No ☐ YesPlease describe and quantify if possible for each grade of glycine for which you are answering "Yes." | | | |
| | | | |
| | | | |
| Anticipated product changesDo you anticipate any changes in terms of the product range, product mix, or marketing of glycine in the future? | | | |
| ☐ No ☐ YesPlease identify, including the time period. | | | |
| | | | |
| | | | |

| IV-25. | Demand tr | ends | |
|--------|-----------|------|--|

| | (a) | How has the demand within the United States for glycine changed since January 1, 2009. What principal factors affect changes in demand? | | | |
|--------|--------|---|------------------------|------------------------|--------------------------|
| | | ☐ Increased | No Change | Decreased | Fluctuated |
| | | | | | |
| | (b) | (b) How has the demand outside the United States (if known) for glycine changed sinc January 1, 2005? What principal factors affect changes in demand? | | | |
| | | Increased | No Change | Decreased | Fluctuated |
| | | | | | |
| IV-26. | Antici | pated demand tren | <u>ds</u> .— | | |
| | (a) | How do you anticipate demand will change within the United States for glycine in the future? What principal factors will affect these changes in demand? | | | |
| | | ☐ Increase | ☐ No Change | Decrease | Fluctuate |
| | | | | | |
| | (b) | How do you antici | pate demand will chang | e outside the United S | tates for alvoine in the |
| | (0) | How do you anticipate demand will change outside the United States for glycine in the future? What principal factors will affect these changes in demand? | | | |
| | | ☐ Increase | ☐ No Change | Decrease | ☐ Fluctuate |
| | | | | | |
| | | | | | |

| IV-27. | Conditions of competition | | |
|--------|--|---|--|
| | (a) | Is the glycine market subject to business cycles or conditions of competition other than the changes in the overall economy? | |
| | | ☐ No ☐ YesPlease explain and estimate the duration of any such cycle. | |
| | | | |
| | (b) | Have the business cycles or conditions of competition for glycine changed since 2005? | |
| | | ☐ No ☐ YesPlease explain any such changes. | |
| | | | |
| IV-28. | . Supply constraintsHas your firm refused, declined, or been unable to supply glycine since January 1, 2005? (Examples include placing customers on allocation or "controlled order entry, declining to accept new customers or renew existing customers, delivering less than the quantity promised, unable to meet timely shipment commitments, etc.). No Yes Please note and document the time period(s) (i.e., month and year), the customer involved, the amount and type of product involved; and the | | |
| | | reason for the allocation. | |
| | | | |
| | | | |
| IV-29. | | comparisons.—How do the market prices of glycine in the U.S. compare with non-U.S. s, if known? Provide specific information as to time periods and regions for any price risons. | |
| U | .S. mark | tet prices are higher | |
| | | | |

| IV-30. | Market studiesPlease provide as a separate attachment to this request any studies, surveys, etc that you are aware of that quantify and/or otherwise discuss glycine supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other majo producing/consuming countries, including China, and (3) the world as a whole. Of particular interest is such data from 2005 to the present and forecasts for the future. | | | |
|--------|---|---|--|--|
| IV-31. | <u>Barriers to trade</u> Are your exports of glycine subject to any tariff or non-tariff barriers to trade in other countries? | | | |
| | □ No □ Yes- | -Please list the countries and descr significant changes in such barri- that are expected to occur in the | ers that have occurred since 2005, or | |
| IV-32. | interchangeable (<i>i.e.</i> , car below, using "A" to indi interchangeable, "F" to it that the products are <i>son</i> | netimes interchangeable, "N" to ind | ne applications)? Please indicate fied country-pair are <i>always ently</i> interchangeable, "S" to indicate | |
| | Country-pair | China | Other countries | |
| | United States | | | |
| | China | | | |
| | ¹ For any country-pair the factors that limit or pre | producing glycine that is sometimes of eclude interchangeable use: | r never interchangeable, please explain | |
| | | | | |

IV-33. Factors other than price.—Are differences other than price (*i.e.*, quality, availability, transportation network, product range, technical support, *etc.*) between glycine produced in the United States and in other countries a significant factor in your firm's sales of the products? Please indicate below, using "A" to indicate that such differences are *always* significant, "F" to indicate that such differences are *frequently* significant, "S" to indicate that such differences are *sometimes* significant, "N" to indicate that such differences are *never* significant, and "0" to indicate *no familiarity* with products from a specified country-pair.

| Country-pair | China | Other countries |
|---|--|--|
| United States | | |
| China | | |
| ¹ For any country-pair your firm's sales of glycine by such factors: | for which factors other than price <i>always</i> e, identify the country-pair and report the | or frequently are a significant factor in advantages or disadvantages imparted |
| | | |
| | | |
| | | |
| | | |